Literature DB >> 15041716

Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker.

Chang Qi Zhu1, Fiona H Blackhall, Melania Pintilie, Pratibha Iyengar, Ni Liu, James Ho, Taylor Chomiak, Davina Lau, Timothy Winton, Frances A Shepherd, Ming-Sound Tsao.   

Abstract

PURPOSE: Skp2 plays a critical role in cell cycle progression, especially at the G(1)-S transition, putatively through its control of several cell cycle regulator proteins. The Skp2 gene is located on a region of chromosome 5p that is commonly overrepresented in lung cancer. The present study aimed to evaluate Skp2 abnormalities and their prognostic value in non-small cell lung cancer (NSCLC). EXPERIMENTAL
DESIGN: In total 16 NSCLC cell lines and 163 primary tumors were included in studies to measure Skp2 relative gene copy number, mRNA abundance, and protein level. The tumors were also evaluated for p27 protein expression level and ras mutation. These values were correlated with the clinical and pathological features of the patients.
RESULTS: Skp2 relative gene copy number aberrations were found in 88 and 65% of NSCLC cell lines and primary tumors, respectively. Overrepresentation was especially common among squamous cell carcinoma (74%). Both gene copy overrepresentation (13%) and loss (35%) were found in adenocarcinoma. Skp2 relative gene copy number was significantly correlated with mRNA and protein levels, but none of these were correlated with p27 protein levels. Neither high Skp2 protein expression nor ras mutation was prognostically significant. In NSCLCs with ras mutation, however, high Skp2 protein expression was a significant independent poor prognostic marker.
CONCLUSION: There appears to be a synergistic interaction between high Skp2 protein expression and ras mutation with negative impact on the survival of NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041716     DOI: 10.1158/1078-0432.ccr-03-0470

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

Review 1.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

2.  Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163.

Authors:  Lin Su; Dongrui Han; Jingwen Wu; Xueyun Huo
Journal:  Tumour Biol       Date:  2015-10-19

3.  Phosphorylation of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) by Akt promotes stability and mitogenic function of S-phase kinase-associated protein-2 (Skp2).

Authors:  Gyun Jee Song; Kristen L Leslie; Stacey Barrick; Tatyana Mamonova; Jeremy M Fitzpatrick; Kenneth W Drombosky; Noah Peyser; Bin Wang; Maria Pellegrini; Philip M Bauer; Peter A Friedman; Dale F Mierke; Alessandro Bisello
Journal:  J Biol Chem       Date:  2014-12-09       Impact factor: 5.157

4.  Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo.

Authors:  Zheng Wei; Xian Jiang; Fengjun Liu; Haiquan Qiao; Baoguo Zhou; Bo Zhai; Lianfeng Zhang; Xuwen Zhang; Likun Han; Hongchi Jiang; Geoffrey W Krissansen; Xueying Sun
Journal:  Tumour Biol       Date:  2012-12-11

Review 5.  New insights on the function of SCF ubiquitin E3 ligases in the lung.

Authors:  Nathaniel M Weathington; Rama K Mallampalli
Journal:  Cell Signal       Date:  2013-05-14       Impact factor: 4.315

6.  FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.

Authors:  Tao Zuo; Runhua Liu; Huiming Zhang; Xing Chang; Yan Liu; Lizhong Wang; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

7.  Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.

Authors:  Chang-Qi Zhu; Svetlana N Popova; Ewan R S Brown; Dalia Barsyte-Lovejoy; Roya Navab; Warren Shih; Ming Li; Ming Lu; Igor Jurisica; Linda Z Penn; Donald Gullberg; Ming-Sound Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-28       Impact factor: 11.205

8.  Clinical relevance of SKP2 alterations in metastatic melanoma.

Authors:  Amy E Rose; Guimin Wang; Douglas Hanniford; Stefano Monni; Ting Tu; Richard L Shapiro; Russell S Berman; Anna C Pavlick; Michele Pagano; Farbod Darvishian; Madhu Mazumdar; Eva Hernando; Iman Osman
Journal:  Pigment Cell Melanoma Res       Date:  2010-10-21       Impact factor: 4.693

9.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.

Authors:  D Chitale; Y Gong; B S Taylor; S Broderick; C Brennan; R Somwar; B Golas; L Wang; N Motoi; J Szoke; J M Reinersman; J Major; C Sander; V E Seshan; M F Zakowski; V Rusch; W Pao; W Gerald; M Ladanyi
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

Review 10.  Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer.

Authors:  David Frescas; Michele Pagano
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.